NCT02956499View on ClinicalTrials.gov

Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 24, 2016

Primary Completion Date

July 3, 2017

Study Completion Date

July 3, 2017

Conditions
Fungal Infection
Interventions
DRUG

APX001 single dose 1

DRUG

APX001 single dose 2

DRUG

APX001 single dose 3

DRUG

APX001 single dose 4

DRUG

APX001 single dose 5

DRUG

APX001 single dose 6

DRUG

APX001 multiple dose 1

DRUG

APX001 multiple dose 2

DRUG

APX001 multiple dose 3

DRUG

APX001 multiple dose 4

DRUG

Matching Placebo

Trial Locations (2)

9728 NZ

PRA Health Sciences, Groningen

Unknown

PRA Health Sciences, Groningen

Sponsors
All Listed Sponsors
lead

Basilea Pharmaceutica

INDUSTRY

NCT02956499 - Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects | Biotech Hunter | Biotech Hunter